MediWound Ltd. (MDWD) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Yavne, イスラエル. 現CEOは Ofer Gonen.
MDWD を有する IPO日 2014-03-20, 111 名の正社員, に上場 NASDAQ Global Market, 時価総額 $187.38M.
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
